A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation

Grants and Contracts Details

StatusActive
Effective start/end date6/27/25 → 6/27/27

Funding

  • Alexion Pharmaceuticals: $20,000.00